Several studies, including post hoc mediation analyses from the EMPA‐REG OUTCOME trial and CANVAS Program, have shown that SGLT2 inhibitors can cause an initial increase in erythropoietin (EPO) levels, leading to a rise in hematocrit, hemoglobin, and soluble transferrin receptor levels, as well as counteracting serum ferritin, hepcidin, and iron overload [14-16,23,24]. Here, EPO is linked to Tangier disease.